Miniaturized whole blood ADCC assay of depressed effector activity in cancer patients.
The ADCC test has been miniaturized to use 0.05 ml of whole blood per test as ADCC effectors. A linear dose response was shown by dilutions of 0.05 ml of blood down to a 1:16 dilution. ADCC effector activities of 40 patients with lung cancer and four with leukemia were markedly less than the activity of 200 normal subjects. Melanoma patients did not have comparable statistically significant loss of ADCC activity.